AI Blood Test Spots Recurrence Risk

A new blood test utilizing artificial intelligence and epigenetic signatures shows significant promise in identifying early-stage breast cancer and predicting recurrence risk. Researchers found that these detectable signals in the bloodstream, originating from dead cells, could distinguish between healthy individuals and those with early breast cancer with 95% accuracy. This advancement is particularly noteworthy as it can complement mammography, which sometimes misses cancers.

The test also analyzes rare, aggressive cell signatures to pinpoint patients at higher risk of recurrence, even those initially considered low-risk. While this method demonstrated an 81% accuracy in distinguishing between patients who experienced recurrence and those who did not, experts stress that further extensive research is crucial. Larger, longitudinal studies are required to confirm its efficacy in routine screening and its impact on long-term patient outcomes.